<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 1-yr-old Japanese male infant developed <z:hpo ids='HP_0012115'>hepatitis</z:hpo>-associated <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA), and anti-thymocyte globulin (ATG) plus <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> A (CsA) was administered without any appreciable effects </plain></SENT>
<SENT sid="1" pm="."><plain>Laboratory examination of the patient's serum obtained before therapy revealed various autoantibodies, such as PA-IgG, anti-platelets, anti-<z:chebi fb="0" ids="9160">single-stranded DNA</z:chebi> (ssDNA), and anti-<z:chebi fb="0" ids="4705">double-stranded DNA</z:chebi> (dsDNA) antibodies (Abs) in addition to anti-DRS-1 Abs and anti-moesin Abs, both of which are known to be detectable in approximately 40% of <z:hpo ids='HP_0000001'>all</z:hpo> patients presenting with AA </plain></SENT>
<SENT sid="2" pm="."><plain>He was therefore treated with 17.5 mg/kg/d rituximab 5.5 months after ATG/CsA therapy </plain></SENT>
<SENT sid="3" pm="."><plain>The same rituximab therapy was repeated three times once a month thereafter </plain></SENT>
<SENT sid="4" pm="."><plain>His neutrophil counts started to increase 50 d after the first rituximab therapy and he achieved a complete remission at 16 months after the last rituximab administration </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of the autoantibodies including anti-ssDNA, dsDNA, DRS-1, and moesin became undetectable when he attained the remission </plain></SENT>
<SENT sid="6" pm="."><plain>Anti-CD20 monoclonal antibody therapy may be effective in a subset of patients with AA characterized by the presence of autoantibodies </plain></SENT>
</text></document>